This three party relationship has been established to support a previously established collaboration between Icagen and Pfizer for the discovery of compounds which modulate specific sodium ion channels
Bob Yonke, founder and CEO of Advanced Medical Partners, said: “The combination of AMPI and HealthTronics will allow our physician partners to benefit from HealthTronics’s scale and exclusive
In preclinical research, PNT2258 has shown promising single agent efficacy, combination therapy efficacy and relevant drug-dose response for multiple cancer types including both hematological and solid tumors. ProNAi
The open-label, single-arm Phase I study will assess the tolerability, pharmacokinetic profile and antitumor activity of increasing doses of SGN-33 in combination with Revlimid in up to 30
Safis Solutions is currently interviewing virology laboratories as candidates to conduct the study, which is expected to begin shortly. The purpose of the study is to perfect the
Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing technology with high content phenotypic analyses in cultured human cells. The initial project will
This collaboration will involve a comparison of slides created with NSB’s newly developed NanoCones surface technology and the current industry standard. NSB has agreed to fund the collaboration.
The appellate court issued an order prohibiting regulatory approval of Ranbaxy’s product in Canada until Pfizer’s enantiomer (calcium salt) patent expires in July 2010. Ranbaxy may seek a
The Court also denied Perrigo’s motion for summary judgment based on non- infringement. The case will now proceed to trial with the trial date not having been set.
This decision comes following an appeal the company filed after a previous negative opinion was adopted by the CHMP in November 2007 and only applies to UCB’s filing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.